Research and experimental development on natural sciences and engineering
XELLIA PHARMACEUTICALS AS
Revenue 2024
NOK 83.1m
Operating profit
NOK 7.3m
Equity
NOK 707.2m
Incorporated
1994
Employees
30
Share capital
NOK 223.3m
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 83.1m | |
| Total operating costs | 75.9m | |
| Operating profit (EBIT) | 7.3m | |
| Net financial items | 78.9m | |
| Profit for the year | 74.4m |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 781.3m | |
| of which current assets | 262.0m | |
| Equity | 707.2m | |
| Total liabilities | 74.1m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.